Mastitis bovina: estimación de Staphylococcus aureus

Inicio Conocimiento Mastitis bovina: estimación de Staphylococcus aureus

Mastitis bovina: estimación de Staphylococcus aureus

When new remedies or treatments are considered for used in a farming enterprise the main concern is whether the benefit will outweigh the cost and predicted losses. Benefits however should not only be measured in economic terms. In addition to stochastic partial budget models that estimate cost and benefits when using STARTVAC® (HIPRA) mastitis vaccine, a model was developed to calculate the intramammary infection (IMI) dynamics of Staphylococcus aureus (S. aureus).

Sobre este artículo

Autores

Petzer, I. M.; Karzis, J.; Eric Etter, E.

Resumen

The model revealed that the use of this mastitis vaccine provided additional benefits to combat S. aureus IMI in both high and low transmission risk scenarios. Less clinical cases occurred from the first time cycles but the advantages intensified with duration of use.

Productos relacionados

Compartir en